BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Malfertheiner P, Megraud F, Rokkas T, Gisbert JP, Liou JM, Schulz C, Gasbarrini A, Hunt RH, Leja M, O'Morain C, Rugge M, Suerbaum S, Tilg H, Sugano K, El-Omar EM; European Helicobacter and Microbiota Study group. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut 2022:gutjnl-2022-327745. [PMID: 35944925 DOI: 10.1136/gutjnl-2022-327745] [Cited by in Crossref: 13] [Cited by in F6Publishing: 2] [Article Influence: 13.0] [Reference Citation Analysis]
Number Citing Articles
1 Argueta EA, Ho JJC, Elfanagely Y, D’agata E, Moss SF. Clinical Implication of Drug Resistance for H. pylori Management. Antibiotics 2022;11:1684. [DOI: 10.3390/antibiotics11121684] [Reference Citation Analysis]
2 Aumpan N, Mahachai V, Vilaichone R. Management of Helicobacter pylori infection. JGH Open 2022. [DOI: 10.1002/jgh3.12843] [Reference Citation Analysis]
3 Helicobacter pylori Primary and Secondary Antimicrobial Resistance through 22 Years of Culture Experience (2000-2021).. [DOI: 10.21203/rs.3.rs-2196259/v2] [Reference Citation Analysis]
4 Park CH, Song MJ, Jung BW, Park JH, Jung YS. Comparative Efficacy of 14-Day Tegoprazan-Based Triple vs. 10-Day Tegoprazan-Based Concomitant Therapy for Helicobacter pylori Eradication. JPM 2022;12:1918. [DOI: 10.3390/jpm12111918] [Reference Citation Analysis]
5 Bornschein J, Pritchard DM, Malfertheiner P. Letter to the editor:Helicobacter pylorieradication – the proof is not in the symptoms. Gut 2022. [DOI: 10.1136/gutjnl-2022-329057] [Reference Citation Analysis]
6 Kriķe P, Shums Z, Poļaka I, Kikuste I, Vanags A, Tolmanis I, Isajevs S, Liepniece-karele I, Santare D, Tzivian L, Rudzīte D, Song M, Camargo MC, Norman GL, Leja M. The Diagnostic Value of Anti-Parietal Cell and Intrinsic Factor Antibodies, Pepsinogens, and Gastrin-17 in Corpus-Restricted Atrophic Gastritis. Diagnostics 2022;12:2784. [DOI: 10.3390/diagnostics12112784] [Reference Citation Analysis]
7 Tian X, Suo B, Zhang H, Lu H, Li C, Zhang Y, Ren X, Yao X, Zhou L, Song Z. Bismuth, esomeprazole, metronidazole and amoxicillin or tetracycline as a first‐line regimen for Helicobacter pylori eradication: A randomized controlled trial. Helicobacter 2022. [DOI: 10.1111/hel.12935] [Reference Citation Analysis]
8 Koseki M, Sheu M, Tsai K, Ho C, Liu H, Lin H, Lin C, Huang C. Comparison of the incidence of immune thrombocytopenia between adult patients infected with Helicobacter pylori with and without eradication therapy: A retrospective cohort study in Taiwan.. [DOI: 10.21203/rs.3.rs-2196609/v1] [Reference Citation Analysis]
9 Lanas A, Santilli F. Aspirin and Helicobacter pylori interaction. The Lancet 2022;400:1560-1561. [DOI: 10.1016/s0140-6736(22)02000-1] [Reference Citation Analysis]
10 de Arbulo MG, Tamayo E, Bujanda L, Mendibil L, Mendiola J, Cilla G, Montes M. Helicobacter pylori Primary and Secondary Antimicrobial Resistance through 22 Years of Culture Experience (2000-2021).. [DOI: 10.21203/rs.3.rs-2196259/v1] [Reference Citation Analysis]
11 Nguyen LT, Nguyen VB, Tran TV, Duong HQ, Le LTT, Phuong MHT, Nguyen T. Efficacy of Helicobacter pylori Eradication Based on Rabeprazole–Bismuth–Tetracycline–Tinidazole Regimen in Vietnamese Patients with Duodenal Ulcers. Gastroenterology Insights 2022;13:365-376. [DOI: 10.3390/gastroent13040036] [Reference Citation Analysis]
12 Yang H, Guan L, Hu B, Moreira L. Detection and Treatment of Helicobacter pylori: Problems and Advances. Gastroenterology Research and Practice 2022;2022:1-10. [DOI: 10.1155/2022/4710964] [Reference Citation Analysis]
13 Bordin DS, Livzan MA, Osipenko MF, Mozgovoy SI, Andreyev DN, Maev IV. The key statements of the Maastricht VI consensus. jour 2022. [DOI: 10.31146/1682-8658-ecg-205-9-5-21] [Reference Citation Analysis]
14 Mahmoud A, Abuelazm M, Ahmed AAS, Abdalshafy H, Abdelazeem B, Brašić JR. Efficacy and Safety of Polaprezinc-Based Therapy versus the Standard Triple Therapy for Helicobacter pylori Eradication: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Nutrients 2022;14:4126. [PMID: 36235778 DOI: 10.3390/nu14194126] [Reference Citation Analysis]
15 Hu Y, Zhuang Y, Gou H, Xie C, Ge Z. Editorial: The interactions between gastrointestinal microbiota and Helicobacter pylori in diseases. Front Cell Infect Microbiol 2022;12:1043906. [DOI: 10.3389/fcimb.2022.1043906] [Reference Citation Analysis]
16 Uspenskiy YP, Baryshnikova NV, Krasnov AA, Petlenko SV, Apryatina VA. Topical issues of prevention of stomach cancer: A review. Consilium Medicum 2022;24:358-364. [DOI: 10.26442/20751753.2022.5.201922] [Reference Citation Analysis]